180 related articles for article (PubMed ID: 15300803)
21. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
[TBL] [Abstract][Full Text] [Related]
22. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.
Palomba ML; Roberts WK; Dao T; Manukian G; Guevara-Patiño JA; Wolchok JD; Scheinberg DA; Houghton AN
Clin Cancer Res; 2005 Jan; 11(1):370-9. PubMed ID: 15671568
[TBL] [Abstract][Full Text] [Related]
23. Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model.
Weaver EA; Chen CY; May SM; Barry ME; Barry MA
Hum Gene Ther; 2011 Sep; 22(9):1095-100. PubMed ID: 21770794
[TBL] [Abstract][Full Text] [Related]
24. Irradiation up-regulates CD80 expression through induction of tumour necrosis factor-alpha and CD40 ligand expression on B lymphoma cells.
Ishikawa F; Nakano H; Seo A; Okada Y; Torihata H; Tanaka Y; Uchida T; Miyake H; Kakiuchi T
Immunology; 2002 Jul; 106(3):354-62. PubMed ID: 12100723
[TBL] [Abstract][Full Text] [Related]
25. Enhanced immunogenicity of B cell lymphoma genetically engineered to express both B7-1 and interleukin-12.
Pizzoferrato E; Chu NR; Hawley TS; Lieu FH; Barber BH; Hawley RG; Watts TH; Berinstein NL
Hum Gene Ther; 1997 Dec; 8(18):2217-28. PubMed ID: 9449375
[TBL] [Abstract][Full Text] [Related]
26. A therapeutic vaccine using Salmonella-modified tumor cells combined with interleukin-2 induces enhanced antitumor immunity in B-cell lymphoma.
Grille S; Moreno M; Brugnini A; Lens D; Chabalgoity JA
Leuk Res; 2013 Mar; 37(3):341-8. PubMed ID: 23107422
[TBL] [Abstract][Full Text] [Related]
27. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.
Liu Y; Xia D; Li F; Zheng C; Xiang J
Cancer Gene Ther; 2005 Feb; 12(2):122-32. PubMed ID: 15565183
[TBL] [Abstract][Full Text] [Related]
28. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.
Levitsky HI; Montgomery J; Ahmadzadeh M; Staveley-O'Carroll K; Guarnieri F; Longo DL; Kwak LW
J Immunol; 1996 May; 156(10):3858-65. PubMed ID: 8621924
[TBL] [Abstract][Full Text] [Related]
29. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for murine K1735 melanoma: combinatorial use of recombinant adenovirus expressing CD40L and other immunomodulators.
Peter I; Nawrath M; Kamarashev J; Odermatt B; Mezzacasa A; Hemmi S
Cancer Gene Ther; 2002 Jul; 9(7):597-605. PubMed ID: 12082460
[TBL] [Abstract][Full Text] [Related]
32. Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells.
Dotti G; Savoldo B; Yotnda P; Rill D; Brenner MK
Blood; 2002 Jul; 100(1):200-7. PubMed ID: 12070028
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody.
Chen W; Yu Y; Shao C; Zhang M; Wang W; Zhang L; Cao X
Immunol Lett; 2001 May; 77(1):17-23. PubMed ID: 11348665
[TBL] [Abstract][Full Text] [Related]
34. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells.
Kikuchi T; Crystal RG
Hum Gene Ther; 1999 May; 10(8):1375-87. PubMed ID: 10365667
[TBL] [Abstract][Full Text] [Related]
36. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
37. Adenovirus-mediated LIGHT gene modification in murine B-cell lymphoma elicits a potent antitumor effect.
Hu G; Liu Y; Li H; Zhao D; Yang L; Shen J; Hong X; Cao X; Wang Q
Cell Mol Immunol; 2010 Jul; 7(4):296-305. PubMed ID: 20418899
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for medullary thyroid carcinoma by a replication-defective adenovirus transducing murine interleukin-2.
Zhang R; Minemura K; De Groot LJ
Endocrinology; 1998 Feb; 139(2):601-8. PubMed ID: 9449631
[TBL] [Abstract][Full Text] [Related]
39. Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment.
Chen HW; Huang HI; Lee YP; Chen LL; Liu HK; Cheng ML; Tsai JP; Tao MH; Ting CC
Cancer Immunol Immunother; 2002 Aug; 51(6):341-8. PubMed ID: 12111122
[TBL] [Abstract][Full Text] [Related]
40. Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles.
Bereta M; Bereta J; Park J; Medina F; Kwak H; Kaufman HL
Cancer Gene Ther; 2004 Dec; 11(12):808-18. PubMed ID: 15359290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
